Holland & Knight Represents BioResource International in Sale to Novus International

PHILADELPHIA (March 8, 2024) – Holland & Knight advised global biotechnology company BioResource International Inc. (BRI) on its sale to Novus International Inc. The deal was announced March 5.

The acquisition will allow Novus, a nutrition company based in Missouri that provides solutions for the global animal agriculture industry, to serve its customers better and expand its innovation pipeline.

Headquartered in Durham, North Carolina, BRI is a leading developer and supplier of feed additives that help poultry, swine and aqua producers optimize performance and gut health while maximizing profits in a sustainable manner. BRI's products include Versazyme® protease feed additive, Xylamax® xylanase feed enzyme, Dymanase® mannanase enzyme, Phytamax® granulated, thermostable, microbial 6-phytase enzyme, and EnzaPro® enzyme and direct-fed microbials, among others.

Holland & Knight's representation of BRI was led by Partner Colby Smith and Associates Leah Simon and Kelcie Ouilette. They were assisted by Partners Eric Rubin and Brandon Bloom and Associates Jiyeon Barta, Charnae Supplee and Allison Krause.

TNCP LLC, a wholly owned subsidiary of TruNorth Capital Partners LLC, served as financial advisor to BRI.

More information on the transaction can be found here.

Holland & Knight regularly ranks among the leading M&A and private equity law firms in reputable, benchmarking league tables published by Bloomberg, LSEG (formerly Refinitiv), Mergermarket, PitchBook and The Deal. In 2023, the firm ranked among the top 5 most active law firms in the U.S. and top 10 globally for its work in the space. Through the HK Deal Flow℠ program, Holland & Knight facilitates deal leads for clients and prospective clients by matching acquisition or capital raising opportunities with buyers and investors.